Stem Cell-Derived Extracellular Vesicle Therapy in Ischemic Brain Injuries

Area of Science:

• Neuroscience
• Regenerative Medicine
• Biotechnology

Background:

• Ischemic brain injury (IBI), encompassing stroke and global cerebral injury, poses significant clinical challenges with limited effective neurological repair strategies.
• Extracellular vesicles (EVs), particularly stem cell-derived EVs (SC-EVs), are emerging as potent cell-free therapeutic agents due to their intercellular communication roles and regenerative potential.

Purpose of the Study:

• To provide a comprehensive review of the therapeutic applications of SC-EVs in treating IBI.
• To compare different SC-EV sources, elucidate their mechanisms of action, and discuss advancements in SC-EV engineering.
• To address challenges in preclinical-to-clinical translation, including standardization and ethical considerations.

Main Methods:

• Review of existing literature on SC-EVs for IBI treatment.
• Analysis of SC-EV sources, mechanisms (immunomodulation, neurogenesis, mitochondrial transfer, myelin repair), and engineering strategies.
• Evaluation of preclinical findings, clinical trial readiness, and ethical implications.

Main Results:

• SC-EVs exhibit regenerative and angiogenic effects comparable to stem cells, offering a promising cell-free therapy for IBI.
• Multifaceted mechanisms of SC-EVs include immunomodulation, neurogenesis, mitochondrial transfer, and myelin repair.
• Engineering SC-EVs enhances targeting and efficacy, while standardization is crucial for reproducible in vivo studies.

Conclusions:

• SC-EVs represent a significant advancement in cell-free therapy for IBI, with diverse therapeutic mechanisms and potential for enhancement through bioengineering.
• Bridging the gap between preclinical research and clinical trials requires standardized protocols and careful consideration of ethical and equity issues for responsible translation.